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Abstract: Ricin is a protein toxin classified as a bioterror agent, for which there are no 
known treatment options available after intoxication. It is composed of an enzymatically 
active  A-chain  connected  by  a  disulfide  bond  to  a  cell  binding  B-chain.  After 
internalization by endocytosis, ricin is transported retrogradely to the Golgi and ER, from 
where the ricin A-chain is translocated to the cytosol where it inhibits protein synthesis and 
thus induces cell death. We have identified cytoplasmic phospholipase A2 (PLA2) as an 
important  factor  in  ricin  retrograde  transport.  Inhibition  of  PLA2  protects  against  ricin 
challenge,  however  the  toxin  can  still  be  endocytosed  and  transported  to  the  Golgi. 
Interestingly, ricin transport from the Golgi to the ER is strongly impaired in response to 
PLA2 inhibition. Confocal microscopy analysis shows that ricin is still colocalized with the 
trans-Golgi marker TGN46 in the presence of PLA2 inhibitor, but less is colocalized with 
the cis-Golgi marker GM130. We propose that PLA2 inhibition results in impaired ricin 
transport through the Golgi stack, thus preventing it from reaching the ER. Consequently, 
ricin cannot be translocated to the cytosol to exert its toxic action.  
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1. Introduction 
Ricin is a very potent toxin isolated from the seeds of the castor oil plant Ricinus communis, and it 
is classified as a potential bioterror agent, for which no treatment is available [1]. Ricin is a protein 
toxin,  consisting  of  two  polypeptide  chains  A  and  B,  linked  via  a  disulfide  bridge.  The  B-chain 
mediates the binding to glycolipids or glycoproteins with a terminal  galactose at the cell surface, 
followed by endocytic uptake into the cell [2,3]. After endocytosis, a fraction of the internalized ricin 
is transported retrogradely from endosomes to the Golgi, and further on to the endoplasmic reticulum 
(ER). In the ER, the disulfide bridge between the A- and B-chain is reduced, and the enzymatically 
active  A-chain  is  translocated  to  the  cytosol  where  it  inactivates  the  28S  ribosomal  RNA  and 
subsequently inhibits protein synthesis and induces cell death (for review see e.g., [4]). As there is no 
proven, safe treatment for ricin intoxication, the investigation into the molecular details of the uptake 
and transport of ricin into cells is highly important. It has been shown that inhibition of retrograde 
transport of ricin not only protects cells [5] but also mice [6] from ricin challenge, suggesting the 
retrograde route as a potential therapeutic target. Importantly, studies of the retrograde transport of 
ricin will contribute to our knowledge about this pathway. 
The endocytosis and retrograde transport of toxins are complicated processes, regulated by a variety 
of factors (for reviews, see e.g., [4,7]). During the last decades, it has become evident that also lipids 
play a major role in toxin transport. For instance cholesterol has been shown to be important for the 
intracellular transport of both  ricin  and the bacterial  toxin  Shiga toxin (Stx)  [8–10]. Furthermore, 
depletion  of  sphingolipids  facilitates  endosome  to  Golgi  transport  of  ricin  [11],  and  it  has  been 
demonstrated that the composition of glycosphingolipids in the cellular membrane is crucial for the 
uptake of Stx [12–16]. Polyunsaturated fatty acids also regulate Stx transport [17], and the general 
membrane  bilayer  composition  of  lipids  play  an  important  role  in  intracellular  transport,  as  does 
membrane tubule formation [18,19]. It is therefore apparent that not only other proteins, but also lipids 
play an important role in uptake mechanisms and retrograde transport of protein toxins. 
Phospholipase  A2s  (PLA2s)  are  enzymes  catalyzing  the  hydrolysis  of  glycerophospholipids  into 
lysophospholipids  and  free  fatty  acids  [20].  The  presence  of  lysophospholipids  may  increase  the 
curvature on the cytosolic leaflet of organelle membranes, hence PLA2s are involved in both membrane 
shape formation and function [21,22]. In addition, membrane tubule formation seems to be dependent on  
PLA2  activity,  as  for  instance  the  Brefeldin  A  (BFA)-stimulated  induction  of  Golgi  membrane  
tubulation [23,24]. It was recently demonstrated that PLA2 enzymes are involved in the earliest steps of 
membrane tubule formation at the trans-Golgi Network (TGN) [25]. Endosomal membrane tubulation 
has also been demonstrated to be dependent on PLA2 activity [26,27]. Furthermore, PLA2 is important 
for intracellular trafficking events such as recycling of transferrin (Tf) and  low-density lipoprotein 
receptor (LDLR) [26,28], and the degradative pathway of LDL and epidermal growth factor (EGF) [28]. 
In addition, it has been demonstrated that PLA2 antagonists can block constitutive cycling of chimeric 
temperature-sensitive  proteins  between  the  Golgi  and  ER  [29].  Most  of  these  studies  have  been 
performed  using  small  molecule  inhibitors  of  PLA2  activity,  such  as  ONO-RS-082  (ONO)  and 
bromoenol lactone (BEL). However, the involvement of PLA2 activity in these processes has been 
further demonstrated by the stimulation of Golgi membrane tubulation and retrograde trafficking to the 
ER  by PLA2  activating peptide (PLAP)  [30] and by inhibition  of  LPAT (lysophosphatidylcholine Toxins 2011, 3                         
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acyltransferase), which catalyzes the reverse reaction of PLA2 [31]. Furthermore, PLA2 activity is 
induced by the addition of cholesterol, and is involved in the cholesterol-induced vesiculation of the 
Golgi apparatus [32].  
Given the importance of PLA2 activity in membrane tubulation and intracellular trafficking events, 
we decided to investigate the role of PLA2 in the retrograde transport of ricin. To this end we used the 
PLA2 antagonists ONO and BEL, and specially designed ricin molecules to study the intracellular 
trafficking of the toxin. The data clearly demonstrate a role of PLA2 activity in the retrograde transport 
of ricin. Treatment with the PLA2 inhibitor ONO protected the cells against ricin challenge, and ricin 
transport to the ER was strongly impaired. Ricin could still be endocytosed and transported to the 
TGN, suggesting that it was  the TGN-to-ER  transport step that  was dependent  on PLA2  activity. 
Altogether the data indicate that PLA2 is an important player in the retrograde transport of ricin. 
2. Materials and Methods 
2.1. Materials 
All  chemicals  were  purchased  from  Sigma-Aldrich  (St.  Louis,  MO,  USA)  if  not  otherwise  
noted. H2
35SO4 and [
3H]Leucine were purchased from Hartman Analytic (Braunschweig, Germany), 
D-[2-
3H(N)]-mannose and Na
125I were from Perkin Elmer (Boston, MA, USA). ONO-RS-082 (ONO) 
was purchased from ENZO Life Sciences (Plymouth, PA, USA), and bromoenol lactone (BEL) from 
Sigma-Aldrich. Rabbit anti-ricin antibody was from Sigma Aldrich, sheep anti-TGN46 antibody was 
from AbD Serotec (Oxford, UK), and mouse anti-GM130 was from BD Bioscience (San Jose, CA, 
USA). Ricin-sulf-1 (RS1), ricin with a modified ricin A-subunit containing a tyrosine sulfation site, 
and ricin-sulf-2 (RS2), ricin with a modified ricin A-subunit containing a tyrosine sulfation site and 
three  partially  overlapping  N-glycosylation  sites  in  the  C-terminal,  was  produced  and  purified  as 
described earlier [33]. Plasmids encoding TPST-1-EGFP and TPST-2-EGFP were a kind gift from  
Dr. Ludger Johannes (Institut Curie, Paris, France). 
2.2. Cell Culture and Transfection 
HEp-2  cells  were  maintained  in  Dulbecco’s  modified  Eagle’s  medium  (Invitrogen,  Carlsbad,  
CA,  USA)  supplemented  with  10%  fetal  calf  serum,  100  units/mL  penicillin  and  100  µg/mL 
streptomycin,  at  37  °C   under  5%  CO2.  For  cytotoxicity  and  endocytosis  assays,  the  cells  were  
seeded  out  in  24-well  plates  at  a  density  of  5  ×  10
4  cells/well  one  day  before  the  experiment.  
For  the  sulfation  and  mannosylation  assays,  cells  were  seeded  in  6-well  plates  at  a  density  of  
2 ×  10
5 cells/well, and for confocal microscopy studies the cells were seeded in 6-well plates with two 
coverslips per well at a density of 1 ×  10
5 cells/well, one day before the experiment. For transfection 
with  pTPST-1-EGFP  and  pTPST-2-EGFP,  cells  on  coverslips  were  transfected  using  Fugene  6 
according to the manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany) one day before 
use in confocal microscopy studies. Toxins 2011, 3                         
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2.3. Cytotoxicity Assay 
Cells  grown  in  24-well  plates  were  washed  twice  in  leucine-free  HEPES-buffered  medium  
before addition of inhibitors at indicated concentrations for 30 min. Increasing concentrations of ricin 
(1–1000 ng/mL) were added, and the cells incubated for 3 h at 37 °C . The medium was then replaced 
with leucine-free HEPES-buffered medium containing 2 µCi/mL [
3H]Leucine, and the cells incubated 
further for 20 min. The proteins were precipitated with 5% (w/v) trichloracetic acid (TCA), washed 
once in 5% (w/v) TCA, and then dissolved in 0.1 M KOH. The incorporation of radioactively labeled 
leucine was quantified, and IC50 calculated as the concentration of toxin giving a 50% reduction in 
protein synthesis. Fold protection was then calculated as the ratio between IC50 for inhibitor-treated 
cells compared to control cells. 
2.4. Sulfation Assay 
The  cells  were  washed  twice  with  sulfate-free  medium  supplemented with  2  mM  L-glutamine, 
followed by incubation with 0.2 mCi/mL H2
35SO4 in sulfate-free medium for 2.5 h at 37 ° C. The cells 
were  then  incubated  with  inhibitors  at  the  indicated  concentrations  for  30  min  before  addition  of  
ricin-sulf-1 (6 µg/mL) for an additional 2 h. The medium was removed and the cells washed 2 ×  5 min 
with 0.1 M lactose in HEPES-buffered medium, and once in cold PBS on ice before addition of 400 
µL  lysis  buffer  [0.1  M  NaCl,  10  mM  Na2HPO4,  1  mM  EDTA,  1%  Triton  X-100,  60  mM  octyl 
glycopyranoside] supplemented with  Complete protease inhibitors  (Roche Diagnostics, Mannheim, 
Germany).  The  lysate  was  cleared  by  centrifugation  (8000  rpm,  10  min)  and  ricin-sulf-1  was 
immunoprecipitated  with  anti-ricin  antibody,  pre-bound  to  protein  A-sepharose  beads  (Amersham 
Biosciences, Buckinghamshire, UK), overnight at 4 °C . The precipitate was separated by SDS-PAGE 
under reducing conditions, and blotted onto a PVDF membrane (Immobilon-P, Millipore, Billerica, 
MA, USA). The bands were detected by autoradiography and imaged and quantified using PharosFX 
scanner and Quantity One
® 1-D Analysis Software (BioRad Laboratories Inc, Hercules, CA, USA). 
The  total  amount  of  sulfated  proteins  was  determined  by  TCA-precipitation  of  all  
35S-labeled proteins in the lysates. 
2.5. Mannosylation Assay 
The cells were washed twice with glucose-free DMEM, followed by incubation in glucose-free 
DMEM containing 1.8 µL/mL D-(+)-glucose solution (10%) and 0.1 mCi/mL D-[2-
3H(N)]-mannose 
for  2.5  h  at  37  °C .  ONO  was  then  added  at  indicated  concentrations,  in  addition  to  1  µg/mL 
swainsonine, and the cells incubated for another 30 min. Ricin-sulf-2 (6 µg/mL) was then added and 
incubation continued for another 2 h. Subsequently, the cells were treated following the sulfation assay 
protocol described above. The bands were detected using Kodak BioMax MS-film (Sigma-Aldrich), 
scanned and quantified by Quantity One
® 1-D Analysis Software (BioRad Laboratories Inc, Hercules,  
CA, USA). The total amount of mannosylated proteins was determined by TCA-precipitation of all 
 
3H-labeled proteins in the lysates. Toxins 2011, 3                         
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2.6. Endocytosis of 
125I-ricin 
Cells were pre-incubated with 2.5 or 5 µM ONO for 30 min, before addition of 
125I-ricin for 2 h  
at 37 °C . Binding of ricin was measured as the amount of cell-associated ricin after washing with  
ice-cold buffer (0.14 M NaCl, 2 mM CaCl2, 20 mM HEPES; pH 7.0). Endocytosed ricin was measured 
as the amount of 
125I-ricin that was not removed after 2 ×  5 min washing with 0.1 M lactose in 
HEPES-buffered medium. 
2.7. Confocal Microscopy 
The cells grown on glass coverslips were washed once in HEPES-buffered medium before addition 
of 5 µM ONO for 30 min. Ricin-sulf-1 (~1 µg/mL) was added for 15 min, followed by 30 min chase. 
The cells were then washed twice with 0.1 M lactose in HEPES-buffered medium, and twice in PBS. 
The cells were fixed with 10% formalin-solution, and permeabilized in 0.1% Triton X-100. Blocking 
solution, 5% fetal calf serum in PBS, was then added for 30 min, before incubation with the appropriate 
primary  and  secondary  antibodies.  Fluorophore-labeled  secondary  antibodies  were  obtained  from 
Jackson  ImmunoResearch  Laboratories  (West  Grove,  PA,  USA).  The  cells  were  mounted  in 
Prolong®Gold containing DAPI for staining of the nuclei (Molecular Probes, Eugene, OR, USA), and 
imaged on laser scanning confocal microscope LSM 510 DUO (Carl Zeiss, Jena, Germany). Images 
were prepared and analyzed with the LSM Image Browser software (Carl Zeiss) or ImageJ software 
(NIH, Bethesda, USA). Colocalization was quantified using the LSM Image Examiner (Carl Zeiss), 
and presented as percentage colocalization compared to control. 
3. Results 
3.1. PLA2 Inhibitor Protects Cells against Ricin 
In order to examine the potential involvement of PLA2 enzymes in the intracellular transport of 
ricin, we took advantage of the commonly used PLA2 inhibitors ONO-RS-082 (ONO) and bromoenol 
lactone (BEL). First we investigated if treatment with ONO had any effect on the overall cytotoxicity 
of  ricin  in  HEp-2.  The  cells  were  pretreated  with  two  different  concentrations  of  ONO,  before 
exposure to increasing concentrations of ricin. Toxin response curves were created, and as can be seen 
in Figure 1A, pre-treatment with 5 µM ONO had a significant protective effect against ricin. As a 
quantitative measure of this effect, the fold protection was calculated as the concentration of ricin 
giving a 50% reduction in protein synthesis in treated cells compared to untreated cells (Figure 1C), 
and 5 µM  ONO  resulted in  an  almost  9-fold protection against ricin.  Cytoplasmic PLA2s  can be 
divided into Ca
2+-dependent and Ca
2+-independent (iPLA2) enzymes [20], and ONO is an inhibitor of 
both of these classes. BEL is an irreversible inhibitor of iPLA2, and was also tested in ricin toxicity 
assays. At a concentration of 2.5 µM, which is commonly used to inhibit iPLA2 activity [26,29], BEL 
did not have any protective effect against ricin (Figure 1B,C). These data then suggest that it is the 
Ca
2+-dependent PLA2 enzymes that are involved in the ricin intoxication process. Toxins 2011, 3                         
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Figure  1.  PLA2  inhibitor  ONO  protects  against  ricin  challenge.  HEp-2  cells  were  
pre-treated with inhibitors ONO (A) or BEL (B) for 30 min before addition of ricin for 3 h 
followed by [
3H]leucine for 20 min. Protein biosynthesis was measured by [
3H]leucine 
incorporation, and toxicity curves were generated; (C) The fold protection against ricin 
was calculated at 50% inhibition of protein biosynthesis and compared to control which 
was set to 1. The average of at least three experiments is shown, and error bars indicate 
standard error of the mean (SEM). 
 
Shiga toxin (Stx) is a bacterial toxin which is also endocytosed and transported retrogradely from 
the Golgi to the ER, and finally the cytosol (see e.g., [34]). Interestingly, treatment with 2.5 or 5 µ M 
ONO  had no significant effect  on the toxicity  of Stx in  these cells  (Supplementary  Figure S1A), 
indicating that Stx transport to the cytosol of HEp-2 cells is not dependent on PLA2 activity. 
3.2. Ricin Sulfation Is Strongly Increased in Response to PLA2 Inhibition 
Given the observed protection against ricin by the PLA2 inhibitor ONO, we were interested in 
determining which step in the retrograde transport pathway that was impaired in the presence of this 
compound. As mentioned in the introduction, PLA2 activity is important for endosomal membrane 
tubulation, and PLA2 enzymes are involved in several endosomal trafficking events [26,28]. It could 
therefore be speculated that ricin transport from endosomes to the Golgi could be impaired in response to 
PLA2 inhibition. In order to address this, we took advantage of a modified ricin molecule, ricin-sulf-1, 
with a tyrosine sulfation site attached C-terminally to the ricin A-chain. As sulfation is a modification 
that occurs mainly in the TGN [35], it is possible to measure the amount of internalized ricin reaching 
the Golgi apparatus using radioactively labeled sulfate. Interestingly, ricin transport to the Golgi is not Toxins 2011, 3                         
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impaired in the presence of inhibitors ONO (Figure 2A) or BEL (Figure 2B). Surprisingly, the amount 
of sulfated ricin was strongly increased in response to inhibitor treatment. Control experiments show 
that there was no effect on total protein sulfation in the cells. Quantification of the data shows that 
there is as much as an 8-fold increase in the amount of sulfated ricin-sulf-1 in response to 2.5 µ M 
ONO and a 10-fold increase for 5 µM ONO. For BEL, the effect on ricin sulfation was weaker, but 
still giving a 2.5-fold increase in response to 10 µM BEL. These data indicate that ricin is being 
transported to the Golgi apparatus in presence of inhibitors, and they show that the degree of sulfation 
is actually increased after inhibitor treatment. The sulfation of Stx was not altered in response to ONO 
(Supplementary Figure S1B). 
Figure 2. Increased sulfation in response to PLA2 inhibitors. HEp-2 cells were incubated 
with radioactive sulfate for 2.5 h before addition of ONO (A) or BEL (B) for 30 min and 
then ricin-sulf-1 for another 2 h. Ricin was immunoprecipitated from the lysates, and the 
precipitate  separated  by  SDS-PAGE.  The  amount  of  sulfated  ricin  (
35S-RS1)  was 
visualized by autoradiography, and the relative change compared to control was quantified. 
The  total  amount  of  sulfated  proteins  was  determined  by  TCA-precipitation  of  all  
35S-labeled proteins in the lysates. The autoradiogram from one representative experiment 
is shown, and the bar graph shows the average of at least three experiments with error bars 
representing standard error of the mean (SEM). 
 
Increased ricin sulfation could be explained by an increase in the internalization of the toxin. In 
order to examine this possibility, endocytosis of 
125I-labelled ricin was analyzed. As can be seen from 
Figure 3A, there was no significant change in the amount of endocytosed ricin in response to ONO, 
demonstrating that PLA2 activity is not required for ricin internalization. 
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Figure  3. Reduced transport to the ER in presence of PLA2 inhibitor ONO. (A) After  
pre-treatment with the indicated concentrations of ONO for 30 min, 
125I-ricin was added to 
the  HEp-2  cells  and  incubation  continued  for  2  h.  Endocytosed  ricin  was  measured  
as  the amount of 
125I-ricin  that was not  removed after washing  with  0.1 M  lactose in  
HEPES-buffered  medium.  The  average  of  three  experiments  is  shown,  with  error  bars 
representing  standard  error  of  the  mean  (SEM);  (B)  HEp-2  cells  were  incubated  with 
radioactive mannose for 2.5 h before addition of ONO for 30 min and then ricin-sulf-2 for 
another 2 h. Ricin was immunoprecipitated from the lysates, and the precipitate separated 
by SDS-PAGE. The bands were detected using Kodak BioMax MS-film (Sigma-Aldrich), 
quantified and presented as percentage of mannosylated ricin compared to control. The 
experiment  was  repeated  twice,  and  a  representative  experiment  is  shown.  The  total 
amount of mannosylated proteins was determined by TCA-precipitation of all 
3H-labeled 
proteins in the lysates. 
 
3.3. Ricin Transport to the Endoplasmic Reticulum is Dependent on PLA2 Activity 
As  described  in  the  introduction,  ricin  is  endocytosed  and  retrogradely  transported  from  early 
endosomes,  through  the  Golgi  apparatus  and  to  the  endoplasmic  reticulum  (ER),  before  it  is 
translocated  to  the  cytosol  where  it  exerts  its  cytotoxic  effect.  The  decreased  toxicity  of  ricin  in 
response to PLA2 inhibition, in combination with the increased sulfation signal, led us to investigate if 
the transport of the toxin from the Golgi to the ER might be inhibited. To this end we used a modified 
ricin molecule, ricin-sulf-2, containing a modified A-chain with N-glycosylation sites in combination 
with radioactively labeled mannose. As mannosylation is an ER-specific modification, this gives a 
measure of how much of the internalized ricin is being transported to the ER. The data presented in 
Figure 3B shows a dramatic decrease in mannosylation of ricin-sulf-2 after treatment with 5 µM ONO, 
indicating that the transport of ricin to the ER is strongly impaired. Quantification shows that there is a 
close to 90% reduction in ricin mannosylation in the presence of 5 µM ONO. Control experiments 
show a moderate reduction (~30%) in total mannosylation in response to ONO. 
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3.4. Localization of Ricin and Golgi Markers in the Presence of PLA2 Inhibitor ONO 
The  sulfation  and  mannosylation  data  suggest  that  PLA2  activity  is  essential  for  Golgi-to-ER 
transport of ricin, and that PLA2 inhibition thereby protects the cells against ricin intoxication. ONO 
and BEL are known to cause disruption of the Golgi cisternae [23,24], but as ricin is strongly sulfated 
in the presence of the inhibitors it seems evident that ricin is transported to the Golgi also under these 
conditions. To get a clearer picture of what is happening to the Golgi in response to PLA2 inhibition, 
and where ricin is localized under these conditions, we performed confocal microscopy studies were 
we stained cells for ricin in combination with Golgi markers. In Figure 4A we show the localization of 
the trans-Golgi marker TGN46 and the cis-Golgi marker GM130 in untreated cells and cells treated 
with 5 µM ONO. As can be clearly seen from the images, both TGN46 and GM130 staining show that 
the inhibitor induces fragmentation of the Golgi as reported previously  [23,24]. The quantification 
(Figure  4B)  shows  that  the  apparent  colocalization  between  TGN46  and  GM130  is  decreased  
in  response  to  ONO,  indicating  that  the  inhibitor  induces  a  separation  between  the  TGN  and  
the cis-Golgi.  
Figure  4.  Localization  of  ricin  in  response  to  PLA2  inhibition.  (A–B)  After  
pre-treatment  with  5  µM  ONO  for  30  min,  HEp-2  cells  were  fixed  and  subjected  to 
immunofluorescence  analysis  with  the  indicated  antibodies.  Colocalization  between  the 
Golgi  markers  GM130  and  TGN46  was  quantified,  and  presented  as  %  colocalization 
compared to control (set to 100%); (C–E) After pre-treatment with 5 µM ONO for 30 min, 
ricin-sulf-1 was added to the cells for 15 min followed by chase for 30 min. The cells were 
washed  with  0.1  M  lactose  to  remove  surface-bound  ricin,  fixed  and  subjected  to 
immunofluorescence analysis with the indicated antibodies. The relative colocalization was 
determined, and presented as percentage colocalization relative to control. Representative 
images are shown, and quantification is from at least three independent experiments with 
error bars representing standard error of the mean (SEM). 
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Figure 4. Cont. 
 
To analyze the localization of ricin under the same conditions, we stained cells for ricin in addition 
to TGN46 and GM130 (Figure 4C–E). As can be seen from the images (Figure 4C,D), and more 
clearly from the quantification of colocalization (Figure 4E), ricin is colocalized with TGN46 to the 
same extent both in the absence and presence of ONO, while there is a decrease in colocalization with 
GM130 upon treatment with the inhibitor (from approximately 30% before treatment to 20% after 
treatment). This indicates that ricin is able to be transported to the TGN, but cannot to the same extent 
be  transported  to  the  cis-Golgi.  The  localization  of  Stx  was  not  altered  in  response  to  ONO 
(Supplementary Figure S2), demonstrating that the change in localization of ricin is not just a result of 
the ONO-induced change in Golgi structure. An accumulation of ricin in TGN over time could also be 
observed by confocal analysis (Supplementary Figure S3), supporting the idea that ricin is inhibited 
from being transported further along the retrograde transport route.  
The increased sulfation seen in response to PLA2 inhibition may be due to either more ricin being 
transported to the TGN, more efficient sulfation in the TGN, or an accumulation of ricin in the TGN as 
it is inhibited from being transported further on along the retrograde pathway and finally degraded. As 
the amount of total protein sulfation is not affected by the inhibitors, a general increase in the activity 
of sulfotransferases does not seem to be a likely explanation. To explore if the treatment with PLA2 
inhibitor  is  affecting  the  localization  of  the  two  main  sulfotransferases  TPST  (Tyrosyl  Protein 
SulfoTransferase)-1 and TPST-2, we expressed GFP-tagged versions of these enzymes in HEp-2 cells. 
The cells were transfected prior to treatment with ONO and exposure to ricin, the localization of the Toxins 2011, 3                         
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TPSTs was then examined by confocal microscopy, and the colocalization with Golgi-markers and ricin 
was quantified. As the images in Figure 5A (TPST-1) and 5B (TPST-2) show, the sulfotransferases are 
mainly localized to the TGN in untreated cells, as expected. Upon addition of ONO, their localization 
became more dispersed, as observed also for TGN46. The quantification (Figure 5C) shows that the 
colocalization  of  TPST-1  and  TPST-2  with  TGN46  is  practically  unchanged  upon  treatment.  In 
addition, colocalization between the sulfotransferases and ricin was also unaffected. These data show 
that although the Golgi is dispersed upon treatment with ONO, both ricin and sulfotransferases are still 
localized to the TGN. These data then suggest that the observed increase in ricin sulfation is probably 
due to either increased transport to the TGN after endocytosis, or accumulation of the toxin in the 
TGN, or a combination of these.  
Figure 5. No change in localization of TPST-1 and TPST-2 in response to PLA2 inhibition. 
HEp-2 cells were transfected with pTPST-1-EGFP (A) and pTPST-2-EGFP (B) plasmids 
one day before treatment with 5 µM ONO for 30 min. Ricin-sulf-1 was added for 15 min 
followed  by  chase  for  30  min.  The  cells  were  washed  with  0.1  M  lactose  to  remove 
surface-bound ricin, fixed and subjected to immunofluorescence analysis with the indicated 
antibodies. The relative colocalization was determined by LSM Image Browser software, 
and presented as percentage colocalization relative to control (C). Representative images 
are shown, and the bar graph shows the average with error bars representing standard error 
of the mean (SEM). 
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Figure 5. Cont. 
 
4. Discussion 
In this study we have shown that PLA2 activity is important for the retrograde transport of ricin 
from TGN to the ER, and that a PLA2 inhibitor is able to protect cells against the toxic effects of ricin. 
The  superfamily  of  PLA2  enzymes  consists  of  15  groups  comprising  secretory  and  cytosolic 
enzymes. In our studies, we have used inhibitors against cytosolic PLA2s, and this group can be further 
divided into Ca
2+-sensitive (group IV PLA2s) and Ca
2+-insensitive (Group VI, VII and VIII PLA2s or 
iPLA2s) isoforms [36]. Both inhibitors used in this work have been widely used in studies of PLA2 
activity and its role in membrane trafficking and maintenance of the Golgi architecture [21,23–26,28]. 
ONO is a broad inhibitor against cytosolic PLA2s, and its effect is reversible [37], while BEL on the 
other hand is reported to be an irreversible inhibitor of iPLA2 enzymes [38,39]. In the toxicity assay 
(Figure 1), we could only use BEL at a concentration of up to 2.5 µ M, as higher concentrations of BEL 
(5 and 10 µ M) turned out to inhibit protein synthesis also in the absence of ricin. At a concentration of 
2.5 µM, we could not observe any protective effects for BEL, although concentrations even lower than 
this (1 µM) has been shown to inhibit iPLA2 activity [26,29–31]. In the sulfation assay, BEL could be 
used at a concentration of 10 µM without having any effect on total protein sulfation levels, and at this Toxins 2011, 3                         
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concentration BEL resulted in a significant increase in ricin sulfation. It has been reported that at such 
high concentrations (10 µM) BEL also inhibits Ca
2+-dependent PLA2 in addition to iPLA2 [25]. Given 
the lack of effects on ricin toxicity and sulfation at low concentrations of BEL, we suggest that it is 
most likely the Ca
2+-dependent PLA2 enzymes that are involved in ricin retrograde transport. More 
thorough  analyses  are  required  to  distinguish  between  the  different  PLA2  groups,  for  instance  by 
depleting the cells of the separate isoforms by siRNA. 
One  candidate  might  be  the  Group  IVA  cPLA2,  cPLA2α.  This  enzyme  has  been  reported  to 
associate preferentially with the Golgi complex, and it was recently demonstrated that cPLA2α controls 
formation of intercisternal tubular continuities, suggesting it to be involved in transport through the 
Golgi complex [40]. For instance, it was shown that depletion of cPLA2α suppressed the intra-Golgi 
transport  of  cargo  proteins  such  as  vesicular  stomatitis  virus  G  (VSV-G)  [40].  These  authors  also 
explored the possible compensatory role of other PLA2 enzymes in cells lacking cPLA2α (immortalized 
lung fibroblasts from cPLA2α knock-out mice), and they found that the Ca
2+-independent Group VIIIA 
PLA2 seemed to play a role. Depletion of Group VIIIA PLA2 in these cells resulted in an accumulation 
of the anterograde cargo VSV-G in the cis-Golgi as shown by colocalization with GM130, and a 
marked delay in protein progression across the Golgi stack [40]. Further studies are needed to examine 
if these PLA2 isoforms are important for retrograde transport of ricin.  
The inhibitor ONO was also used in ricin toxicity assays in other cell lines, and in some cell lines a 
protective effect could be seen, whereas in others the inhibitor alone was toxic to the cells at the tested 
concentrations (data not shown). The reason for this difference between cell lines is unknown, but may 
be due to differences in the repertoire of PLA2 enzymes.  
As  mentioned  in  the  introduction,  PLA2  activity  is  also  important  for  endosomal  membrane 
tubulation [26,27] which could suggest that PLA2 inhibition would impair endosome to Golgi transport 
of ricin. Surprisingly, both the sulfation assay and confocal data show that ricin transport to the TGN  
is  not  impaired  in  presence  of  the  inhibitors.  However,  ricin  transport  from  TGN  to  the  ER  is  
strongly impaired by ONO treatment, showing that PLA2 activity is important for this specific step in 
the  retrograde  route.  The  involvement  of  PLA2  in  Golgi-to-ER  transport  has  been  demonstrated 
previously for KDELR-G and TGN38-G, which are chimeric proteins of the thermosensitive luminal 
domain of VSV-G and  the cytoplasmic  and transmembrane domains  of the KDELR  and TGN38, 
respectively [29]. However, these are chimeric proteins that are transported only at the permissive 
temperature, and it cannot be concluded that all normal Golgi-to-ER trafficking is PLA2 dependent. 
Also, PLA2 does not seem to play any role in the retrograde transport of the bacterial toxin Shiga toxin 
(Stx) as the inhibitors did not cause any protective effects against this toxin (Supplementary Figure 
S1A).  This  clearly  shows  that  proteins  following  different  retrograde  transport  routes  do  not 
necessarily have the same requirements. One interesting study with the PLA1 enzyme iPLA1γ shows 
that this phospholipase is involved in transfer of Golgi membrane to the ER in presence of BFA and 
also transport of the cholera toxin B-subunit from Golgi to the ER [41]. However it is not involved in 
COPI- and Rab6-dependent retrograde transport represented by ERGIC-53 recycling and Golgi-to-ER 
transport of Stx [41], demonstrating different requirements for transport of different cargo. One should 
therefore be careful not to draw general conclusion from studies of single cargos, but study the cargo 
of interest independently. 
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5. Conclusions 
By using inhibitors against cytosolic PLA2s we have studied the potential role of PLA2 enzymes  
in  the  retrograde  transport  of  ricin.  The  data  show  that  PLA2  inhibition  protects  against  ricin  
challenge. Treatment with inhibitors does not interfere with ricin endocytosis nor does it decrease 
endosome-to-Golgi  transport,  however  Golgi-to-ER  transport  is  strongly  impaired  resulting  in  a 
protective  effect  against  the  toxin.  These  results  emphasize  the  importance  of  lipids  and  lipid 
composition  of  membranes  for  intracellular  transport,  and  gives  new  insights  into  the  retrograde 
transport of ricin. 
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